Insight in the activity of the EPO-FGF23 signaling pathway in rare hereditary anemias with varies degrees of hemolysis and ineffective erythropoiesis and varying circulating EPO concentrations, will add to the understanding of the pathophysiology and bone complications of these diseases. The gene discussed is EPO; the disease is anemia.